Daiichi Sankyo, Lilly Drug At Top Of U.S. FDA List For Investigation
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo's and U.S. drug maker Eli Lilly's co-developed Effient (prasugrel) blood-thinner leads a U.S. FDA list of drugs on a schedule of planned investigations
Daiichi Sankyo's and U.S. drug maker Eli Lilly's co-developed Effient (prasugrel) blood-thinner leads a U.S. FDA list of drugs on a schedule of planned investigations. The drug is on a quarterly FDA list of early investigations into problems linked to various drugs. In Effient's case, the agency has cited reports of thrombotic thrombocytopenic purpura in patients administered the drug. A Lilly spokeswoman said the firm has seen one or perhaps two reports of TTP associated with Effient since it won U.S. approval a year ago. (Click here for more) |